Financial Performance - The company reported a net loss of RMB 253,422,000 for the year ended December 31, 2025, compared to a net loss of RMB 182,242,000 for the previous year, representing an increase of 39% in losses[5]. - The net loss for the year increased by 39.1% to RMB 253.4 million, compared to RMB 182.2 million for the previous year[63]. - The basic and diluted loss per share for 2025 was RMB (2.44), compared to RMB (1.95) in 2024, reflecting increased losses per share[92]. - The total loss attributable to ordinary equity holders of the parent was RMB 253,422 thousand for 2025, an increase from RMB 182,242 thousand in 2024[109]. - The company reported a total revenue of RMB 165,000, primarily from early sales of palopegteriparatide before official approval[53]. - Gross profit amounted to RMB 19,000, indicating a focus on patient accessibility and clinical needs during the pilot phase[55]. - Total assets increased to RMB 977.3 million from RMB 293.8 million in the previous year, while total liabilities rose to RMB 215.2 million from RMB 52.5 million[51]. - The company reported a pre-tax loss of RMB (253,422,000) for 2025, compared to RMB (182,242,000) in 2024, indicating a significant increase in losses[92]. Research and Development - Research and development costs increased to RMB 93,484,000 in 2025 from RMB 90,521,000 in 2024, reflecting a growth of 3%[5]. - The R&D team consists of 35 full-time employees, with approximately 37% holding PhDs or MDs, and an average of over 16 years of experience in clinical development[41]. - The company has established a scientific advisory board comprising key opinion leaders in endocrinology and pediatrics to support its R&D capabilities[41]. - The company aims to enhance its drug pipeline through milestone-driven early research in collaboration with leading external technology platforms[9]. - The company is focused on expanding its market presence and enhancing its product pipeline through strategic initiatives[119]. Product Development and Commercialization - The company received approval for the commercialization of lonapegsomatropin, its core product, on January 26, 2026, for treating growth hormone deficiency in children aged 3 and above in China[6]. - The company completed the open-label phase of its Phase 3 study for palopegteriparatide in January 2026, with plans to submit a New Drug Application (NDA) in the second half of 2026[10]. - Lonapegsomatropin has completed Phase 3 pivotal trials in China for treating growth hormone deficiency in children aged 3 to 17, demonstrating statistically significant efficacy compared to short-acting growth hormone[15]. - The commercialization strategy for Lonapegsomatropin focuses on high-value specialty products targeting the out-of-pocket market, aiming to position it as a best-in-class long-acting growth hormone therapy[19]. - The company plans to implement a comprehensive commercialization plan for lonapegsomatropin to tap into the significant domestic market potential in China, including Hong Kong, Macau, and Taiwan, ensuring a continuous supply of the drug for local patients[22]. Strategic Partnerships and Collaborations - A strategic cooperation agreement was signed with Dongfulong Technology Group on November 6, 2025, to advance the development and industrial application of dual-chamber lyophilized formulation technology[6]. - The company is expanding its pipeline through strategic collaborations, including a project agreement with Crystal Holdings on February 5, 2026, focusing on endocrine and metabolic therapies[9]. - Strategic partnerships have been established with Anke Bio and Shanghai Pharmaceuticals to enhance market penetration and develop pediatric treatment capabilities[21]. - A strategic collaboration was established with Crystal Clear Holdings to enhance long-term R&D capabilities in endocrine and metabolic therapy areas[39]. - A strategic cooperation agreement was signed with the China Rare Disease Alliance to expand collaboration in pediatric growth and development beyond achondroplasia[40]. Technology and Innovation - The DCD technology has been successfully developed as a drug delivery platform, with patents covering multiple technical dimensions, enhancing intellectual property protection[24]. - The DCD system integrates the drug and diluent in a sealed dual-chamber configuration, simplifying the reconstitution and administration process, thereby improving patient safety and compliance[25]. - The company holds 60 issued patents and 72 pending patent applications in China, including 9 issued patents related to lonapegsomatropin, expiring on September 28, 2037[44][45]. Market Access and Financial Strategy - The company has established a robust market access strategy supported by evidence-based medicine and academic-driven interactions[19]. - The company plans to accelerate the commercialization of core products and clinical development of pipeline candidates as part of its strategic outlook[48]. - The company has completed the technology transfer for core product bulk drug substance, with local process validation expected to be completed by 2027[23]. - The net proceeds from the global offering amounted to approximately HKD 672.3 million (equivalent to RMB 620.2 million) after deducting underwriting commissions and offering expenses[87]. - The company has not conducted any significant acquisitions or disposals of subsidiaries, associates, or joint ventures as of December 31, 2025[77]. Employee and Operational Insights - Total employee costs for the year reached approximately RMB 144.4 million, compared to RMB 98.8 million in the previous year[47]. - The internal commercialization team is highly specialized, with about 20% of frontline members holding master's degrees and nearly one-third recruited from management positions in other pharmaceutical companies[20]. - The company aims to optimize team structure and expand capabilities to support execution efficiency and market expansion as commercialization progresses[20]. Regulatory and Compliance - The company cannot guarantee the successful development or marketing of lonapegsomatropin and palopegteriparatide, advising shareholders and potential investors to act cautiously[30]. - The company is preparing for regulatory submissions, including import BLA and local production BLA for its biopharmaceutical products[116]. - The company is committed to adhering to the Hong Kong Stock Exchange's listing rules and standards[116].
维升药业(02561) - 2025 - 年度业绩